The FINER Clinical Trial - Madelaine is a participant in the FINER study

Опубликовано: 02 Апрель 2025
на канале: Breast Cancer Trials
292
0

The FINER clinical trial aims to control cancer for longer in patients with advanced ER-positive and HER2-negative breast cancer.

The most common subtype of breast cancer is hormone receptor-positive, HER2 negative (ER+/HER2-). Endocrine (hormone) treatments with drugs called CDK 4/6 inhibitors are effective to treat ER-positive, HER2-negative breast cancers. However, in advanced cancer, the cancer eventually grows or spreads despite initial endocrine treatment in most cases. That means this treatment is not effective anymore and other treatments are needed for these resistant cancers.

All living cells (including tumour cells) have functions that make them develop, grow, survive and die. The PI3K-AKT-mTOR pathway within cells is important for cell growth and survival, and it may cause some ER-positive cancers to become resistant to endocrine treatments. The drug ipatasertib can prevent the growth of cancer cells through this pathway.

The FINER clinical trial aims to find out if cancer will remain under control for longer in patients given ipatasertib and fulvestrant, compared with the usual treatment of giving fulvestrant on its own.
----------------------------------------------------------------
Breast Cancer Trials is a group of world-leading breast cancer doctors and researchers based in Australia and New Zealand committed to exploring and finding better treatments for people affected by breast cancer through clinical trials research.

Please like this video then visit www.breastcancertrials.org.au to find out more about our current breast cancer clinical trials that may be suitable for you, and ways in which you can help support breast cancer research.

----------------------------------------------------------------

SUBSCRIBE TO OUR YOUTUBE CHANNEL
   / @breastcancertrials  

LET'S CONNECT
Email ►[email protected]
Tel 1800 423 444
WWW ► http://www.breastcancertrials.org.au
Linkedin ►   / 5057154  
Twitter ►   / bctrialsanz  
Facebook ►   / breastcancertrials  
Instagram ►   / breastcancertrials